Skip to main content
. 2023 Dec 7;13:1240318. doi: 10.3389/fonc.2023.1240318

Figure 3.

Figure 3

Forest plot of the efficacy outcomes after anti-CD38 mAbs therapy for RRMM. (A) Overall response rate; (B) Complete response or better rate; (C) Very good partial response or better rate; (D) Minimum residual disease-negative rate.